Apollo Endosurgery Inc (Apollo Endosurgery) is a medical technology company that designs, develops and commercializes medical devices used for the treatment of obesity. The company’s product portfolio comprises endoscopy products such as Orbera Intragastric Balloon System; Apollo ESG system; Apollo REVISE system; Endoscopic Suturing systems and OverStitch endoscopic suturing system. These non-surgical interventional devices are also used in procedures that address or repair a variety of gastrointestinal defects. Apollo Endosurgery's products serve bariatric surgeons and gastroenterologists in providing interventional therapy for obesity and associated co-morbidities. It has a manufacturing facility in the Coyol Free Trade Zone in Alajuela, Costa Rica. Apollo Endosurgery is headquartered in Austin, Texas, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Apollo Endosurgery Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Apollo Endosurgery Inc Company Overview
- Apollo Endosurgery Inc Company Snapshot
- Apollo Endosurgery Inc Pipeline Products and Ongoing Clinical Trials Overview
- Apollo Endosurgery Inc - Pipeline Analysis Overview
- Business Description
- Apollo Endosurgery Inc - Key Facts
- Apollo Endosurgery Inc - Major Products and Services
- Apollo Endosurgery Inc Pipeline Products by Development Stage
- Apollo Endosurgery Inc Ongoing Clinical Trials by Trial Status
- Apollo Endosurgery Inc Pipeline Products Overview
- NOTES Access System
- NOTES Access System Product Overview
- ORBERA Intragastric Balloon System - NASH
- ORBERA Intragastric Balloon System - NASH Product Overview
- Overstitch - Endoscopic Sleeve Gastroplasty
- Overstitch - Endoscopic Sleeve Gastroplasty Product Overview
- OverStitch - Lower GI
- OverStitch - Lower GI Product Overview
- OverStitch - Reflux
- OverStitch - Reflux Product Overview
- X-Tack Endoscopic HeliX Tacking System
- X-Tack Endoscopic HeliX Tacking System Product Overview
- X-Tack Endoscopic HeliX Tacking System Clinical Trial
- Apollo Endosurgery Inc - Key Competitors
- Apollo Endosurgery Inc - Key Employees
- Apollo Endosurgery Inc - Key Employee Biographies
- Apollo Endosurgery Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Apollo Endosurgery Inc, Recent Developments
- Aug 02, 2022: Apollo Endosurgery Reports Record Global Revenue in Second Quarter 2022
- Jul 21, 2022: Apollo Endosurgery to Report Second Quarter Results on August 2, 2022
- Feb 22, 2021: Apollo Endosurgery to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
- Apr 30, 2020: Apollo Endosurgery to Report First Quarter 2020 Results on May 4, 2020
- Mar 24, 2020: Apollo Endosurgery to Report Fourth Quarter and Full Year 2019 Results on March 26, 2020
- Oct 30, 2019: Apollo Endosurgery reports third quarter 2019 results
- Sep 18, 2019: Apollo Endosurgery receives 510(k) clearance for Polypropylene Suture-Anchor Assembly
- Jul 23, 2019: Apollo Endosurgery reports second quarter 2019 results
- Jun 26, 2019: Apollo Endosurgery enrols final patient for ESG procedure trial
- Jun 13, 2019: Apollo Endosurgery announces US labeling update on the ORBERA Intragastric Balloon System
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Apollo Endosurgery Inc Pipeline Products and Ongoing Clinical Trials Overview
- Apollo Endosurgery Inc Pipeline Products by Equipment Type
- Apollo Endosurgery Inc Pipeline Products by Indication
- Apollo Endosurgery Inc Ongoing Clinical Trials by Trial Status
- Apollo Endosurgery Inc, Key Facts
- Apollo Endosurgery Inc, Major Products and Services
- Apollo Endosurgery Inc Number of Pipeline Products by Development Stage
- Apollo Endosurgery Inc Pipeline Products Summary by Development Stage
- Apollo Endosurgery Inc Ongoing Clinical Trials by Trial Status
- Apollo Endosurgery Inc Ongoing Clinical Trials Summary
- NOTES Access System - Product Status
- NOTES Access System - Product Description
- ORBERA Intragastric Balloon System - NASH - Product Status
- ORBERA Intragastric Balloon System - NASH - Product Description
- Overstitch - Endoscopic Sleeve Gastroplasty - Product Status
- Overstitch - Endoscopic Sleeve Gastroplasty - Product Description
- OverStitch - Lower GI - Product Status
- OverStitch - Lower GI - Product Description
- OverStitch - Reflux - Product Status
- OverStitch - Reflux - Product Description
- X-Tack Endoscopic HeliX Tacking System - Product Status
- X-Tack Endoscopic HeliX Tacking System - Product Description
- X-Tack Endoscopic HeliX Tacking System - Closure of Mucosal and Submucosal Defects in the Gastrointestinal Tract Using the Novel X-Tack Endoscopic Suturing Device
- X-Tack Endoscopic HeliX Tacking System - Comparison of the Performance of Standard Through the Scope (TTS) Clip Versus X-tack Suture for Closure of Gastrointestinal Defects
- Apollo Endosurgery Inc, Key Employees
- Apollo Endosurgery Inc, Key Employee Biographies
- Apollo Endosurgery Inc, Other Locations
- Apollo Endosurgery Inc, Subsidiaries
- Glossary
- Apollo Endosurgery Inc Pipeline Products by Equipment Type
- Apollo Endosurgery Inc Pipeline Products by Development Stage
- Apollo Endosurgery Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Steris Plc
- Spatz FGIA, Inc
- Johnson & Johnson
- Cook Medical Inc
- Medtronic Plc
- Allurion Technologies, Inc.
- Medicone
- Boston Scientific Corp
- Olympus Corp
- ReShape Lifesciences Inc
